Category: Sanofi

16 UK biotech companies you should know about

The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the…

Continue Reading 16 UK biotech companies you should know about

The future of diabetes treatment: Is a cure possible?

Diabetes has become an epidemic, sentencing over 537 million people worldwide to lifelong medication. Science is striving to find a diabetes treatment that can cure this chronic disease, but how close are we? Diabetes is the major cause of blindness, kidney failure, heart attack, and stroke. It is estimated that…

Continue Reading The future of diabetes treatment: Is a cure possible?

Highlights of the 2024 JPM Healthcare Conference

Like every year, 2024 kicked off with a bang for the biotech industry, as thousands gathered at the J.P. Morgan Health Conference (JPM) that took place in San Francisco, last week. One of the largest healthcare conventions in the world, JPM recaps the glories as well as the gloom of…

Continue Reading Highlights of the 2024 JPM Healthcare Conference

The best countries for biotech according to the OECD

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech companies (2,840) and an R&D intensity added value of 17%, the U.S. remains a strong leader in the industry. But…

Continue Reading The best countries for biotech according to the OECD

Revolutionizing acne treatment with CRISPR technology

Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, and in its crosshairs, initially, is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population. This week, we talk to Xavier Duportet, CEO…

Continue Reading Revolutionizing acne treatment with CRISPR technology

Five AI drug discovery companies you should know about

Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at five of the top AI drug discovery companies.  The…

Continue Reading Five AI drug discovery companies you should know about

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Nine biotech companies to watch in 2024

As 2024 unfolds, the biotechnology industry is brimming with potential, spearheading scientific innovation. This year is particularly exciting as a diverse range of biotech companies are poised to break new ground to tackle global challenges. Here are nine biotech companies we will follow in 2024. Aiolos Bio Aiolos Bio has…

Continue Reading Nine biotech companies to watch in 2024

2 global itepekimab Phase 3 trials for COPD open new US sites

Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are being…

Continue Reading 2 global itepekimab Phase 3 trials for COPD open new US sites

First Wave BioPharma (FWBI) Enters Term Sheet for Merger with ImmunogenX

First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the company has signed a non-binding term sheet for a business combination with ImmunogenX, a clinical-stage biotherapeutics company developing…

Continue Reading First Wave BioPharma (FWBI) Enters Term Sheet for Merger with ImmunogenX

First Wave BioPharma Announces Entry into Term Sheet for

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a strategic U.S. license agreement with a global pharmaceutical company is anticipated to be completed post-closing BOCA RATON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE)…

Continue Reading First Wave BioPharma Announces Entry into Term Sheet for

Elfabrio as effective as Fabrazyme for Fabry, kidney decline: Trial

Elfabrio (pegunigalsidase alfa) is as safe and effective as Fabrazyme (agalsidase beta) and can prevent kidney decline in adults with Fabry disease over two years, according to final data from the BALANCE Phase 3 clinical trial. Infusion-related side effects, in particular, occur significantly less often with Elfabrio than with Fabrazyme,…

Continue Reading Elfabrio as effective as Fabrazyme for Fabry, kidney decline: Trial

Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Turns out Jay Bradner is moving from academia and Novartis to serve as Amgen’s new CSO. Also, the FDA has a new registry of trial sponsors and investigators…

Continue Reading Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

ABSTRACT Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology. Methods: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August…

Continue Reading Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the…

Continue Reading U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

European Bioinformatics Institute | EMBL-EBI hiring Machine Learning Data Scientist in Hinxton, England, United Kingdom

Open Targets (OT) is a unique public-private partnership working to deliver experimental data and informatics platforms that enable researchers to make more informed decisions about target selection for drug discovery. OT is a shared initiative between the European Bioinformatics Institute (EMBL-EBI), a global leader in the management, integration and analysis…

Continue Reading European Bioinformatics Institute | EMBL-EBI hiring Machine Learning Data Scientist in Hinxton, England, United Kingdom

Five Dubai Biopharma Companies To Know About

The Middle East’s industry is rapidly growing, with several key players emerging in the region. Notably, Qatar, Saudi Arabia, and the United Arab Emirates (UAE) are at the forefront of this expansion. Our focus today zeros in on the UAE, particularly Dubai and its biopharma companies, renowned for being one…

Continue Reading Five Dubai Biopharma Companies To Know About

how to obtain a valid patent?

The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process…

Continue Reading how to obtain a valid patent?

Updated Odronextamab Data from Relapsed/Refractory Diffuse

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…

Continue Reading Updated Odronextamab Data from Relapsed/Refractory Diffuse

Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival

Paris: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival (PFS) compared with VRd alone in…

Continue Reading Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival

The mRNA shield against dengue

Swetha Raghavan from the Dengue Vaccine Programme at the National Centre for Biological Sciences (NCBS), said: “Our attempt is a first mRNA dengue vaccine for India as an alternative to traditional approaches. One can choose specific antigenic regions to overcome the challenges of Antibody-Dependent Enhancement, confer protection across multiple serotypes,…

Continue Reading The mRNA shield against dengue

Sanofi – Sarclisa Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant -December 08, 2023 at 09:18 am EST

PARIS – The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival (PFS) compared with VRd alone in transplant-ineligible patients with…

Continue Reading Sanofi – Sarclisa Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant -December 08, 2023 at 09:18 am EST

B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the B-Cell Lymphomas pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphomas pipeline therapeutics…

Continue Reading B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Glioma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “Glioma Pipeline Insight 2023” report provides comprehensive insights about 190+ companies and 130+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product…

Continue Reading Glioma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis

According to a recent announcement, the FDA has placed a clinical hold on the development program for fenebrutinib (Roche), an investigational oral, reversible, and noncovalent Bruton tyrosine kinase (BTK) inhibitor in development for patients with multiple sclerosis (MS).1 The decision was based on 2 recent cases of hepatic transaminase elevations…

Continue Reading FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis

Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…

Continue Reading Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Merck KGaA’s highly anticipated MS drug fails in Phase 3 trial

Merck KGaA’s highly anticipated experimental multiple sclerosis (MS) drug failed to meet its primary endpoint in two Phase 3 trials, the company announced this week. The EVOLUTION trials found that the drug, evobrutinib, didn’t meet its primary endpoint of reducing annualized relapse rates in patients with relapsing MS compared to…

Continue Reading Merck KGaA’s highly anticipated MS drug fails in Phase 3 trial

BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials

According to an announcement, evobrutinib (Merck KGaA/EMD Serono), an investigational Bruton’s tyrosine kinase (BTK) inhibitor in development for patients with multiple sclerosis (MS), did not meet its primary end points of reducing relapse in the phase 3 EVOLUTION trials. The company plans to evaluate the totality of the data for…

Continue Reading BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

RNA- Based Therapeutic Market worth $29.41 Bn by 2031

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global RNA- Based Therapeutic Market– by Drug Class (RNA Aptamer, siRNA, Antisense RNA, mRNA), By Therapeutic Area (Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP)), Trends,…

Continue Reading RNA- Based Therapeutic Market worth $29.41 Bn by 2031

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

Dupixent shown to reduce COPD exacerbations in 2nd clinical trial

Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3 clinical…

Continue Reading Dupixent shown to reduce COPD exacerbations in 2nd clinical trial

Crispr and Cas Gene Market to Hit $6.47 Billion by 2030: Coherent Market Insights (CMI)

CMI Crispr and Cas gene are segment of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) that act as an acquired immune system in bacteria and archaea defend against foreign genetic elements such as viruses. These genes are majorly used for genome editing applications in various industries…

Continue Reading Crispr and Cas Gene Market to Hit $6.47 Billion by 2030: Coherent Market Insights (CMI)

Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation

This article was originally published by Pharmacy Times®. It has been lightly edited. Investigators plan to submit a supplemental biologics license application (sBLA) for dupilumab (Dupixent; Sanofi, Regeneron) at the end of 2023 for the treatment of uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a press release….

Continue Reading Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial -December 01, 2023 at 12:20 pm EST

Sanofi announced the second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial. The NOTUS trial also confirmed that treatment with Dupixent led to rapid and significant improvements…

Continue Reading Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial -December 01, 2023 at 12:20 pm EST

Software Developer – Backend at European Molecular Biology Laboratory (EMBL)

About the team/job We are looking for an enthusiastic and driven Backend Software Developer to join Open Targets at EMBL-EBI. We are open to applicants at different career stages, but we are keen to find someone who wants to embrace cutting-edge technologies in order to tackle complex challenges in drug…

Continue Reading Software Developer – Backend at European Molecular Biology Laboratory (EMBL)

Small Interfering RNA Market revenue to hit USD 67 Billion by 2036, says Research Nester

Research Nester Key small interfering rna market players include GE HealthCare Technologies, Inc., Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis AG. New York , Nov. 29, 2023 (GLOBE NEWSWIRE) — The global small interfering rna (sirna) …

Continue Reading Small Interfering RNA Market revenue to hit USD 67 Billion by 2036, says Research Nester

Small Interfering RNA (SIRNA) Therapeutics Market investigated in the latest research

Small Interfering RNAs, also called as silencing RNA, is a class of double stranded non-coding RNA molecules. These are the most widely used nucleic acid based sequence for interfering expression of specific genes. The siRNAs help to recognize unique pathways and to validate targets for various life threatening diseases such…

Continue Reading Small Interfering RNA (SIRNA) Therapeutics Market investigated in the latest research

EMBL’s European Bioinformatics Institute (EMBL-EBI) in 2023 | Nucleic Acids Research

Abstract The European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) is one of the world’s leading sources of public biomolecular data. Based at the Wellcome Genome Campus in Hinxton, UK, EMBL-EBI is one of six sites of the European Molecular Biology Laboratory (EMBL), Europe’s only intergovernmental life sciences organisation. This…

Continue Reading EMBL’s European Bioinformatics Institute (EMBL-EBI) in 2023 | Nucleic Acids Research

Sanofi, Regeneron eye Dupixent label expansion with promising COPD data

Dupixent appears to have done it again. The monoclonal antibody from Sanofi and Regeneron was successful in treating chronic obstructive pulmonary disease (COPD) in Phase 3 trial data unveiled Monday morning. If Dupixent wins an approval for COPD, that would expand its current indication as an anti-inflammatory therapy for conditions…

Continue Reading Sanofi, Regeneron eye Dupixent label expansion with promising COPD data

2023-11-27 | NDAQ:REGN | Press Release

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per µL), confirming results from the landmark BOREAS pivotal trial Dupixent rapidly and significantly improved…

Continue Reading 2023-11-27 | NDAQ:REGN | Press Release

Phase 3 Clinical Trial for Dupixent Reports Significant Reduced COPD Exacerbations

Trial results expected to accelerate the potential of Dupixent to become the first FDA-approved treatment for chronic obstructive pulmonary disease. Regeneron Pharmaceuticals and Sanofi have announced that a Phase 3 trial evaluating Dupixent (dupilumab) in the treatment of chronic obstructive pulmonary disease (COPD) showed the drug reduced exacerbations by 34%,…

Continue Reading Phase 3 Clinical Trial for Dupixent Reports Significant Reduced COPD Exacerbations

Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

Continue Reading Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

Dupilumab Shown to Reduce COPD Exacerbations Substantially in New Phase 3 Data

Regeneron Pharmaceuticals, Inc., and Sanofi announced new phase 3 data indicating dupilumab (Dupixent) leads to substantial reductions in exacerbations of chronic obstructive pulmonary disease (COPD), adding to its future potential as the first approved COPD biologic treatment.1 “We are highly encouraged by these remarkable results from NOTUS showing a 34%…

Continue Reading Dupilumab Shown to Reduce COPD Exacerbations Substantially in New Phase 3 Data

COPD Exacerbations Reduced Substantially With Dupilumab, Phase 3 Data Shows

Regeneron Pharmaceuticals, Inc., and Sanofi announced new phase 3 data indicating dupilumab (Dupixent) leads to substantial reductions in exacerbations of chronic obstructive pulmonary disease (COPD), adding to its future potential as the first approved COPD biologic treatment.1 “We are highly encouraged by these remarkable results from NOTUS showing a 34%…

Continue Reading COPD Exacerbations Reduced Substantially With Dupilumab, Phase 3 Data Shows

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

Sanofi to accelerate ‘smokers lung’ treatment after phase 3 trial success

Dupixent showed ‘strong efficacy’ in the latest trial, showing a 34% reduction in the rate at which patients’ COPD worsened compared to those who received a placebo. COPD is a chronic obstructive pulmonary disease that damages the lungs over time and causes airflow blockage and breathing-related problems. It is currently…

Continue Reading Sanofi to accelerate ‘smokers lung’ treatment after phase 3 trial success

Sanofi reports positive Phase 3 data on Dupixent for COPD (NASDAQ:SNY)

Panama7/iStock Editorial via Getty Images Sanofi (NASDAQ:SNY) on Monday reported positive data from a second Phase 3 trial of Dupixent (dupilumab) for chronic obstructive pulmonary disease (COPD). Dupixent was found to significantly reduce COPD exacerbations by 34% compared to placebo, meeting the primary endpoint of the trial with “overwhelming” efficacy….

Continue Reading Sanofi reports positive Phase 3 data on Dupixent for COPD (NASDAQ:SNY)

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Sanofi and Regeneron have shared positive results from a late-stage trial of Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD). The phase 3 NOTUS trial has been evaluating the investigational use of Dupixent compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled COPD and evidence of…

Continue Reading Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint -November 27, 2023 at 02:26 am EST

By Pierre Bertrand Sanofi said a second phase three trial of Dupixent met its primary endpoint with what the company said was overwhelming efficacy. Sanofi said that its Notus trial confirmed positive published results from the Phase 3 Boreas trial. The Notus trial found that the treatment “significantly reduced exacerbations”…

Continue Reading Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint -November 27, 2023 at 02:26 am EST

Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint

By Pierre Bertrand Sanofi said a second phase three trial of Dupixent met its primary endpoint with what the company said was overwhelming efficacy. Sanofi said that its Notus trial confirmed positive published results from the Phase 3 Boreas trial. The… Master your money. Subscribe to MarketWatch. Get this article…

Continue Reading Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint

Sanofi looks to widen Dupixent use to treat ‘smoker’s lung’ after second trial win

Sanofi plans to seek U.S. approval for it best-selling anti-inflammatory drug Dupixent to be used in the treatment of “smoker’s lung”, also known as COPD, after a second large trial showed significant benefits. Sanofi, which is collaborating on the drug with Regeneron , said in a statement on Monday…

Continue Reading Sanofi looks to widen Dupixent use to treat ‘smoker’s lung’ after second trial win

Sanofi, Regeneron therapy Dupixent succeeds in Phase 3 COPD trial

LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with the chronic lung disease COPD, its developers said Monday, results that could propel the blockbuster medicine into a massive new market. Dupixent, which is jointly developed by Sanofi and Regeneron Pharmaceuticals, has already racked up…

Continue Reading Sanofi, Regeneron therapy Dupixent succeeds in Phase 3 COPD trial

Latest biotech news: fundraises, deals, clinical trials

Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round  Chinese company Viva Biotech closed…

Continue Reading Latest biotech news: fundraises, deals, clinical trials

Small Interfering RNA (siRNA) Therapeutics Market: Trends,

Small Interfering RNA (siRNA) Therapeutics Market Small Interfering RNA (siRNA) Therapeutics Market Report Scope: This research delves into the complexities of siRNA therapies, providing a broad coverage that includes significant players, developing trends, and breakthrough technologies in the sector. Stakeholders are given an excellent insight, which will help them make…

Continue Reading Small Interfering RNA (siRNA) Therapeutics Market: Trends,

Activist Investor Reported to Take $1B Stake in BioMarin

GEN Edge presents Gene Therapy Briefs, a roundup of commercial developments in gene therapy and other genome editing technologies. Gene Therapy Briefs has long appeared in the journal Human Gene Therapy, published by GEN publisher Mary Ann Liebert Inc., publishers. Elliott Investment Management, a fund manager with approximately $60 billion…

Continue Reading Activist Investor Reported to Take $1B Stake in BioMarin

Astria Therapeutics shares Q3 results, positive phase 1a data, and pipeline expansion By Investing.com

© Reuters. Astria Therapeutics recently reported its third-quarter financial results and provided a corporate update, highlighting its promising Phase 1a data for STAR-0215, a potential preventative treatment for Hereditary Angioedema (HAE). The company also announced the expansion of its pipeline with STAR-0310, a potential therapy for atopic dermatitis. Key takeaways…

Continue Reading Astria Therapeutics shares Q3 results, positive phase 1a data, and pipeline expansion By Investing.com

October 2023 Recap: Drug Pipeline Updates

Drug Pharmacologic Class Proposed Indication Status Cardiovascular Disorders Patisiran (Alnylam) Transthyretin-directed small interfering RNA Treatment of the cardiomyopathy of transthyretin-mediated amyloidosis. Complete Response Letter issued Dermatological Disorders Dupilumab (Regeneron and…

Continue Reading October 2023 Recap: Drug Pipeline Updates

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Key Points Question  Is clonal hematopoiesis of indeterminate potential (CHIP) detected at the time of hematopoietic stem transplant (HCT) associated with increased rates of cardiovascular disease (CVD) among patients with multiple myeloma (MM) following HCT? Finding  In this cohort study of patients with MM undergoing HCT, CHIP was highly prevalent…

Continue Reading Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder

Positive results of in vivo toxicology studies in which AEF0117 shows a favorable therapeutic index >13,000 time the active dose: Chronic oral toxicity studies (6 months in rats and 9 months in dog) allowing for unrestricted chronic treatment in humans. Reproductive toxicology studies showing that AEF0117 does not modify embryonic…

Continue Reading Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Oral and Poster Abstracts 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Research, adult, Translational Research, assays, Plasma Cell Disorders, bioinformatics, Diseases, Lymphoid Malignancies, computational biology, Technology and Procedures, Study Population, Human, molecular testing, omics technologies Dor D. Abelman1,2, Jenna Eagles1*, Stephanie Pedersen1*,…

Continue Reading Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Regeneron Pharmaceuticals, Inc. Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations include the first review of primary endpoint results with longer follow-up from the pivotal trial for linvoseltamab in heavily pre-treated patients with multiple…

Continue Reading Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Regeneron Reports Third Quarter 2023 Financial and Operating Results

Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022 Third quarter 2023 Dupixent® global net sales(recorded by Sanofi) increased 33% to $3.10 billion versus third quarter 2022 Third quarter 2023 U.S. net sales for EYLEA® and EYLEA HD were $1.49 billion, including $43…

Continue Reading Regeneron Reports Third Quarter 2023 Financial and Operating Results

How French pharma giant Sanofi is betting big on AI

The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching…

Continue Reading How French pharma giant Sanofi is betting big on AI

Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressure, liver enzyme, triglyceride, low-density lipoprotein cholesterol, and serum uric acid etc.), and mean reduction of liver fat content…

Continue Reading Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Global Small Interfering Rna Sirna Therapeutics Market Future

Small interfering RNA (siRNA) Therapeutics Market Report Overview Carbolic oil, a mystical concoction of hydrocarbons, aromatics, phenolics, and aromatic nitrogen compounds, finds its place in various industries. Its chemical derivatives serve as building blocks for pharmaceutical drugs, detergents, and more. Small interfering RNA (siRNA) Therapeutics Market Join us as we…

Continue Reading Global Small Interfering Rna Sirna Therapeutics Market Future

Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

October 26, 2023 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

Merck Announces Third-Quarter 2023 Financial Results

October 26, 2023 6:30 am ET Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 8% KEYTRUDA Sales Grew 17% to…

Continue Reading Merck Announces Third-Quarter 2023 Financial Results

Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine -October 25, 2023 at 05:20 pm EDT

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…

Continue Reading Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine -October 25, 2023 at 05:20 pm EDT

2023-10-25 | NDAQ:ALNY | Press Release

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…

Continue Reading 2023-10-25 | NDAQ:ALNY | Press Release

Nemolizumab Promise for Prurigo Nodularis Continues

Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the European Academy of Dermatology and Venereology. In the OLYMPIA 1 study, clinically significant improvements in both itch…

Continue Reading Nemolizumab Promise for Prurigo Nodularis Continues

Combination Influenza/COVID-19 Vaccine Enters Phase 3 Trial, First Participant Dosed

The first participant has been dosed in the phase 3 clinical trial of mRNA-1083, an investigational combination vaccine candidate that protects against influenza and COVID-19 being studied by Moderna. Investigators anticipate enrolling approximately 8000 individuals in the Northern Hemisphere for the trial, according to a Moderna press release.1 ©Kateryna_Kon/stock.adobe.com The…

Continue Reading Combination Influenza/COVID-19 Vaccine Enters Phase 3 Trial, First Participant Dosed

Phase 3 Trial Begins for Combination Influenza and COVID-19 Vaccine

Investigators have dosed the first participant in a phase 3 trial for mRNA-1083 (Moderna), a combination vaccine candidate that provides protection against influenza and COVID-19. Investigators anticipate enrolling approximately 8000 individuals in the Northern Hemisphere for the trial, according to a Moderna press release.1 Image credit: Alernon77 | stock.adobe.com The…

Continue Reading Phase 3 Trial Begins for Combination Influenza and COVID-19 Vaccine

Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company’s exclusive efpeglenatide, a glucagon-like peptide 1 (GLP-1) receptor agonist candidate for treating obesity and diabetes.  Efpeglenatide is a GLP-1 medication to be taken once a week using…

Continue Reading Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

Roche: Roivant’s Ulcerative Colitis Drug Could Lead New Class of Drugs, Maintaining Valuation

Roche ROG is paying $7.1 billion to acquire U.S. and Japan rights to inflammatory bowel disease drug RVT-3101 from Roivant in a deal that has been rumored for months, and we’re not making any changes to our fair value estimate. The value of the drug candidate has skyrocketed in recent…

Continue Reading Roche: Roivant’s Ulcerative Colitis Drug Could Lead New Class of Drugs, Maintaining Valuation

Roche to Pay $7.1B to Get Contender in Tight Inflammatory Bowel Disease Race

Roche is expanding its immunology pipeline by acquiring a Roivant Sciences subsidiary whose Phase 3-ready drug candidate for inflammatory bowel disease addresses a promising novel target that pits the Swiss pharmaceutical giant against contenders from Merck and Sanofi. According to deal terms announced Monday, Roche is paying $7.1 billion up…

Continue Reading Roche to Pay $7.1B to Get Contender in Tight Inflammatory Bowel Disease Race

Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With EoE

(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) showed consistent efficacy and safety for up to one year (52 weeks) in children aged 1 to 11 years with eosinophilic esophagitis. Eosinophilic esophagitis, or EoE,…

Continue Reading Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With EoE

Phase 3 Data Show Teplizumab Slows T1D Progression in Children, Adolescents

Teplizumab is approved by the FDA to delay the onset of clinical stage 3 T1D in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed T1D can prevent disease progression is unknown. New data presented at the…

Continue Reading Phase 3 Data Show Teplizumab Slows T1D Progression in Children, Adolescents

September 2023 Recap: Drug Pipeline Updates

Drug Pharmacologic Class Proposed Indication Status Allergic Disorders Neffy (internal epinephrine; ARS Pharmaceuticals) Non-selective alpha and beta adrenergic agonist Treatment of severe allergic reactions, including anaphylaxis, for adults and children weighing at least 30kg. Complete Response Letter…

Continue Reading September 2023 Recap: Drug Pipeline Updates

RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

(MENAFN– EIN Presswire) RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s global market reports…

Continue Reading RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

DNA Process Development & Manufacturing Summit

With the cell and gene therapy industry surging, rapid advances in mRNA-based therapies, and the advent of DNA vaccines, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years. The DNA Process Development & Manufacturing Summit is the only industry-dedicated forum to focus…

Continue Reading DNA Process Development & Manufacturing Summit

Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration USA – English APAC – English

ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient with neovascular age-related macular degeneration (nAMD)…

Continue Reading Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration USA – English APAC – English

ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…

Continue Reading ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

Docetaxel Not Beneficial for Localized High-Risk Prostate Cancer

Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized prostate cancer, investigators report. Oliver Sartor, MD, of Tulane University Health Services Center in New Orleans, Louisiana, and colleagues presented 10.4 years of median follow-up data from the phase 3 NRG Oncology/RTOG 0521…

Continue Reading Docetaxel Not Beneficial for Localized High-Risk Prostate Cancer

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

Continue Reading Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Cell And Gene Therapy Market Outlook and Opportunities in Grooming Regions 2030

Cell And Gene Therapy Market Size Projections : The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030). Global Cell And Gene Therapy Market 2023 research report represents a detailed overview of the current market situation and…

Continue Reading Cell And Gene Therapy Market Outlook and Opportunities in Grooming Regions 2030

Long-term Eloctate found to reduce all bleed types in trial analyses | Preventive therapy also seen to improve joint health in hemophilia A

Preventive treatment with Eloctate (efmoroctocog alfa) for up to five years led to sustained reductions in all bleed types for children, adolescents, and adults with severe hemophilia A, according to data from two Phase 3 trials and their open-label extension study. New analyses of these pivotal trials also showed improved…

Continue Reading Long-term Eloctate found to reduce all bleed types in trial analyses | Preventive therapy also seen to improve joint health in hemophilia A

Japan firm Takeda’s dengue vaccine gets WHO panel backing, but no nod yet for phase 3 trials in India

New Delhi: A scientific advisory panel under the World Health Organization (WHO) has recommended a vaccine developed by Japanese pharma giant Takeda against dengue — a viral infection caused by the dengue virus (DENV), transmitted to humans through the bite of infected mosquitoes — for use in endemic countries. “The…

Continue Reading Japan firm Takeda’s dengue vaccine gets WHO panel backing, but no nod yet for phase 3 trials in India

REGENERON AND INTELLIA ANNOUNCE EXPANDED RESEARCH COLLABORATION TO DEVELOP CRISPR-BASED THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND MUSCULAR DISEASES

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research…

Continue Reading REGENERON AND INTELLIA ANNOUNCE EXPANDED RESEARCH COLLABORATION TO DEVELOP CRISPR-BASED THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND MUSCULAR DISEASES

Metastatic Prostate Cancer Market Size in the 7MM was ~USD 6400 million in 2022, Estimates DelveInsight

PRESS RELEASE Published October 3, 2023 “The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics”   The Metastatic Prostate…

Continue Reading Metastatic Prostate Cancer Market Size in the 7MM was ~USD 6400 million in 2022, Estimates DelveInsight

Can CAR-NK therapy pick up from where CAR-T left off?

Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white…

Continue Reading Can CAR-NK therapy pick up from where CAR-T left off?

Sanofi, Janssen Enter E.coli Vax Pact

Sanofi has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the Phase 3 vaccine candidate for extraintestinal pathogenic E.coli (9-valent) developed by Janssen. The agreement combines Janssen’s science behind this potential first-in-class product and Sanofi’s worldwide manufacturing footprint and expertise in…

Continue Reading Sanofi, Janssen Enter E.coli Vax Pact

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease (IED) annually, worldwide1,2 Phase 3 clinical trial of vaccine candidate ongoing. Novel ExPEC vaccine expected to complement existing older adult vaccine portfolio Paris, October 3, 2023. Sanofi announces today that it has entered into…

Continue Reading Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Regeneron and Intellia Announce Expanded Research

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)…

Continue Reading Regeneron and Intellia Announce Expanded Research

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

For Immediate Release Chicago, IL – October 2, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Lilly…

Continue Reading The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

Chronic Idiopathic Urticaria Pipeline, Clinical Trials, Emerging Drugs and FDA Approvals 2023 (Updated)

PRESS RELEASE Published September 30, 2023 DelveInsight’s, “Chronic Idiopathic Urticaria Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Idiopathic Urticaria Pipeline landscape. It covers the Chronic Idiopathic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the…

Continue Reading Chronic Idiopathic Urticaria Pipeline, Clinical Trials, Emerging Drugs and FDA Approvals 2023 (Updated)

Chronic Urticaria Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)

PRESS RELEASE Published September 30, 2023 DelveInsight’s, “Chronic Urticaria Pipeline Insight 2023” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline…

Continue Reading Chronic Urticaria Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)